Jade Biosciences (JBIO) Convertible Debt (2024)
Jade Biosciences (JBIO) posted Convertible Debt of $107.6 million for Q4 2024.
Jade Biosciences (JBIO) Convertible Debt (2024) Analysis & Trends
Jade Biosciences' Convertible Debt history runs 1 years deep, the most recent figure standing at $107.6 million for Q4 2024.
- Quarterly Convertible Debt changed N/A year-over-year to $107.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $107.6 million (changed N/A YoY) and the FY2024 annual result came in at $107.6 million, changed N/A from the prior year.
- Convertible Debt was $107.6 million for Q4 2024 at Jade Biosciences.
- Across five years, Convertible Debt topped out at $107.6 million in Q4 2024 and bottomed at $107.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 107.60 Mn |